James M. Mock Sells 689 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNA) CFO James M. Mock sold 689 shares of the firm’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $118.24, for a total value of $81,467.36. Following the completion of the transaction, the chief financial officer now owns 7,269 shares in the company, valued at approximately $859,486.56. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Moderna Price Performance

NASDAQ MRNA opened at $122.82 on Friday. The company has a quick ratio of 3.91, a current ratio of 4.03 and a debt-to-equity ratio of 0.04. The stock has a 50-day moving average of $135.36 and a two-hundred day moving average of $113.67. Moderna, Inc. has a 1-year low of $62.55 and a 1-year high of $170.47.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, beating the consensus estimate of ($3.59) by $0.52. The company had revenue of $167.00 million during the quarter, compared to the consensus estimate of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. Moderna’s revenue was down 91.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.19 EPS. On average, sell-side analysts anticipate that Moderna, Inc. will post -7.46 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on MRNA shares. Royal Bank of Canada raised their target price on Moderna from $135.00 to $160.00 and gave the stock an “outperform” rating in a research note on Monday, June 3rd. Jefferies Financial Group reaffirmed a “buy” rating and issued a $125.00 target price on shares of Moderna in a research note on Tuesday, April 9th. Evercore ISI reaffirmed an “in-line” rating and issued a $120.00 target price on shares of Moderna in a research note on Thursday, June 27th. William Blair reaffirmed a “market perform” rating on shares of Moderna in a research note on Thursday, June 27th. Finally, UBS Group raised their target price on Moderna from $143.00 to $151.00 and gave the stock a “buy” rating in a research note on Tuesday, May 7th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Moderna currently has a consensus rating of “Hold” and a consensus target price of $134.02.

Hedge Funds Weigh In On Moderna

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Ogorek Anthony Joseph NY ADV purchased a new position in shares of Moderna in the 4th quarter valued at about $27,000. Cedar Wealth Management LLC boosted its stake in shares of Moderna by 45.0% in the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after buying an additional 90 shares during the period. Arlington Trust Co LLC boosted its stake in shares of Moderna by 4,833.3% in the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after buying an additional 290 shares during the period. Westside Investment Management Inc. purchased a new position in shares of Moderna in the 1st quarter valued at about $32,000. Finally, Bank & Trust Co purchased a new position in shares of Moderna in the 2nd quarter valued at about $36,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.